1
|
Schwab M, Dezfouli AB, Khosravi M, Alkotub B, Bauer L, Birgani MJT, Multhoff G. The radiation- and chemo-sensitizing capacity of diclofenac can be predicted by a decreased lactate metabolism and stress response. Radiat Oncol 2024; 19:7. [PMID: 38229111 DOI: 10.1186/s13014-024-02399-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 01/08/2024] [Indexed: 01/18/2024] Open
Abstract
BACKGROUND An enhanced aerobic glycolysis ("Warburg effect") associated with an increase in lactic acid in the tumor microenvironment contributes to tumor aggressiveness and resistance to radiation and chemotherapy. We investigated the radiation- and chemo-sensitizing effects of the nonsteroidal anti-inflammatory drug (NSAID) diclofenac in different cancer cell types. METHODS The effects of a non-lethal concentration of diclofenac was investigated on c-MYC and Lactate Dehydrogenase (LDH) protein expression/activity and the Heat shock Protein (HSP)/stress response in human colorectal (LS174T, LoVo), lung (A549), breast (MDA-MB-231) and pancreatic (COLO357) carcinoma cells. Radiation- and chemo-sensitization of diclofenac was determined using clonogenic cell survival assays and a murine xenograft tumor model. RESULTS A non-lethal concentration of diclofenac decreases c-MYC protein expression and LDH activity, reduces cytosolic Heat Shock Factor 1 (HSF1), Hsp70 and Hsp27 levels and membrane Hsp70 positivity in LS174T and LoVo colorectal cancer cells, but not in A549 lung carcinoma cells, MDA-MB-231 breast cancer cells and COLO357 pancreatic adenocarcinoma cells. The impaired lactate metabolism and stress response in diclofenac-sensitive colorectal cancer cells was associated with a significantly increased sensitivity to radiation and 5Fluorouracil in vitro, and in a human colorectal cancer xenograft mouse model diclofenac causes radiosensitization. CONCLUSION These findings suggest that a decrease in the LDH activity and/or stress response upon diclofenac treatment predicts its radiation/chemo-sensitizing capacity.
Collapse
Affiliation(s)
- Melissa Schwab
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany
| | - Ali Bashiri Dezfouli
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany
- Department of Otolaryngology, Head and Neck Surgery, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany
| | - Mohammad Khosravi
- Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
| | - Bayan Alkotub
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany
- Institute of Biological and Medical Imaging (IBMI), Helmholtz Zentrum München, Neuherberg, Germany
| | - Lisa Bauer
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany
| | | | - Gabriele Multhoff
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
- Department of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
| |
Collapse
|
2
|
Gies H, Lupker M, Galy V, Hemingway J, Boehman B, Schwab M, Haghipour N, Eglinton TI. Multi-molecular 14C evidence for mineral control on terrestrial carbon storage and export. Philos Trans A Math Phys Eng Sci 2023; 381:20220328. [PMID: 37807685 PMCID: PMC10642773 DOI: 10.1098/rsta.2022.0328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Accepted: 06/29/2023] [Indexed: 10/10/2023]
Abstract
Compound- and compound class-specific radiocarbon analysis of source-diagnostic 'biomarker' molecules has emerged as a powerful tool to gain insights into terrestrial carbon cycling. While most studies thus far have focused on higher plant biomarkers (i.e. plant leaf-wax n-alkanoic acids and n-alkanes, lignin-derived phenols), tracing paedogenic carbon is crucial given the pivotal role of soils in modulating ecosystem carbon turnover and organic carbon (OC) export. Here, we determine the radiocarbon (14C) ages of glycerol dialkyl glycerol tetraethers (GDGTs) in riverine sediments and compare them to those of higher plant biomarkers as well as markers of pyrogenic (fire-derived) carbon (benzene polycarboxylic acids, BPCAs) to assess their potential as tracers of soil turnover and export. GDGT Δ14C follows similar relationships with basin properties as vegetation-derived lignin phenols and leaf-wax n-alkanoic acids, suggesting that the radiocarbon ages of these compounds are significantly impacted by intermittent soil storage. Systematic radiocarbon age offsets are observable between the studied biomarkers, which are likely caused by different mobilization pathways and/or stabilization by mineral association. This article is part of the Theo Murphy meeting issue 'Radiocarbon in the Anthropocene'.
Collapse
Affiliation(s)
- Hannah Gies
- Department of Earth Sciences, ETH Zürich, 8092 Zürich, Switzerland
| | - Maarten Lupker
- Department of Earth Sciences, ETH Zürich, 8092 Zürich, Switzerland
| | - Valier Galy
- Woods Hole Oceanographic Institution, 360 Woods Hole Road, Falmouth, MA 02543, USA
| | - Jordon Hemingway
- Department of Earth Sciences, ETH Zürich, 8092 Zürich, Switzerland
| | - Brenna Boehman
- MIT-WHOI Joint Program in Oceanography/Applied Ocean Science and Engineering, Cambridge and Woods Hole, MA, USA
| | - Melissa Schwab
- Department of Earth Sciences, ETH Zürich, 8092 Zürich, Switzerland
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - Negar Haghipour
- Department of Earth Sciences, ETH Zürich, 8092 Zürich, Switzerland
- Department of Earth Sciences, ETH Zürich, 8093 Zürich, Switzerland
| | | |
Collapse
|
3
|
Wang F, Dezfouli AB, Khosravi M, Sievert W, Stangl S, Schwab M, Wu Z, Steiger K, Ma H, Multhoff G. Cannabidiol-induced crosstalk of apoptosis and macroautophagy in colorectal cancer cells involves p53 and Hsp70. Cell Death Discov 2023; 9:286. [PMID: 37542074 PMCID: PMC10403543 DOI: 10.1038/s41420-023-01578-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 07/12/2023] [Accepted: 07/25/2023] [Indexed: 08/06/2023] Open
Abstract
Although it has been established that cannabidiol (CBD), the major non-psychoactive constituent of cannabis, exerts antitumoral activities, the exact mechanism(s) via which tumor cells are killed by CBD are not well understood. This study provides new insights into the potential mechanisms of CBD-induced mutual antagonism of apoptosis and macroautophagy using wild type (HCT116 p53wt, LS174T p53wt), knockout (HCT116 p53-/-) and mutant (SW480 p53mut) human colorectal cancer cells (CRC). CBD causes a more pronounced loss in the viability of p53wt cells than p53-/- and p53mut cells, and a 5-week treatment with CBD reduced the volume of HCT116 p53wt xenografts in mice, but had no effect on the volume of HCT116 p53-/- tumors. Mechanistically, we demonstrate that CBD only significantly elevates ROS production in cells harboring wild-type p53 (HCT116, LS174T) and that this is associated with an accumulation of PARP1. CBD-induced elevated ROS levels trigger G0/G1 cell cycle arrest, a reduction in CDK2, a p53-dependent caspase-8/9/3 activation and macroautophagy in p53wt cells. The ROS-induced macroautophagy which promotes the activation of keap1/Nrf2 pathway might be positively regulated by p53wt, since inhibition of p53 by pifithrin-α further attenuates autophagy after CBD treatment. Interestingly, an inhibition of heat shock protein 70 (Hsp70) expression significantly enhances caspase-3 mediated programmed cell death in p53wt cells, whereas autophagy-which is associated with a nuclear translocation of Nrf2-was blocked. Taken together, our results demonstrate an intricate interplay between apoptosis and macroautophagy in CBD-treated colorectal cancer cells, which is regulated by the complex interactions of p53wt and Hsp70.
Collapse
Affiliation(s)
- Fei Wang
- Radiation Immuno-Oncology Project Group, TranslaTUM-Central Institute for Translational Cancer Research, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
- Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
| | - Ali Bashiri Dezfouli
- Radiation Immuno-Oncology Project Group, TranslaTUM-Central Institute for Translational Cancer Research, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Mohammad Khosravi
- Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
| | - Wolfgang Sievert
- Radiation Immuno-Oncology Project Group, TranslaTUM-Central Institute for Translational Cancer Research, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Stefan Stangl
- Radiation Immuno-Oncology Project Group, TranslaTUM-Central Institute for Translational Cancer Research, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Melissa Schwab
- Radiation Immuno-Oncology Project Group, TranslaTUM-Central Institute for Translational Cancer Research, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Zhiyuan Wu
- Radiation Immuno-Oncology Project Group, TranslaTUM-Central Institute for Translational Cancer Research, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Katja Steiger
- Institute for General Pathology and Pathological Anatomy, Technische Universität München, Munich, Germany
| | - Hu Ma
- Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China
| | - Gabriele Multhoff
- Radiation Immuno-Oncology Project Group, TranslaTUM-Central Institute for Translational Cancer Research, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| |
Collapse
|
4
|
Salvermoser L, Flisikowski K, Dressel-Böhm S, Nytko KJ, Rohrer Bley C, Schnieke A, Samt AK, Thölke D, Lennartz P, Schwab M, Wang F, Bashiri Dezfouli A, Multhoff G. Elevated circulating Hsp70 levels are correlative for malignancies in different mammalian species. Cell Stress Chaperones 2023; 28:105-118. [PMID: 36399258 PMCID: PMC9877270 DOI: 10.1007/s12192-022-01311-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 10/28/2022] [Accepted: 11/07/2022] [Indexed: 11/19/2022] Open
Abstract
Circulating Hsp70 levels were determined in feline and porcine cohorts using two different ELISA systems. These comparative animal models of larger organisms often reflect diseases, and especially malignant tumors, better than conventional rodent models. It is therefore essential to investigate the biology and utility of tumor biomarkers in animals such as cats and pigs. In this study, levels of free Hsp70 in the blood of cats with spontaneously occurring tumors were detected using a commercial Hsp70 ELISA (R&D Systems). Sub-analysis of different tumor groups revealed that animals with tumors of epithelial origin presented with significantly elevated circulating Hsp70 concentrations. In addition to free Hsp70 levels measured with the R&D Systems Hsp70 ELISA, levels of exosomal Hsp70 were determined using the compHsp70 ELISA in pigs. Both ELISA systems detected significantly elevated Hsp70 levels (R&D Systems: median 24.9 ng/mL; compHsp70: median 44.2 ng/mL) in the blood of a cohort of APC1311/+ pigs diagnosed with high-grade adenoma polyps, and the R&D Systems Hsp70 ELISA detected also elevated Hsp70 levels in animals with low-grade polyps. In contrast, in flTP53R167H pigs, suffering from malignant osteosarcoma, the compHsp70 ELISA (median 674.32 ng/mL), but not the R&D Systems Hsp70 ELISA (median 4.78 ng/mL), determined significantly elevated Hsp70 concentrations, indicating that in tumor-bearing animals, the dominant form of Hsp70 is of exosomal origin. Our data suggest that both ELISA systems are suitable for detecting free circulating Hsp70 levels in pigs with high-grade adenoma, but only the compHsp70 ELISA can measure elevated, tumor-derived exosomal Hsp70 levels in tumor-bearing animals.
Collapse
Affiliation(s)
- Lukas Salvermoser
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany.
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany.
- Department of Radiology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany.
| | - Krzysztof Flisikowski
- Livestock Biotechnology, School of Live Sciences, Technische Universität München (TUM), Liesel-Beckmannstr 1, 85354, Freising, Germany
| | - Susann Dressel-Böhm
- Vetsuisse Faculty, Division of Radiation Oncology, University of Zurich, Winterthurerstr 258C, CH-8057, Zurich, Switzerland
| | - Katarzyna J Nytko
- Vetsuisse Faculty, Division of Radiation Oncology, University of Zurich, Winterthurerstr 258C, CH-8057, Zurich, Switzerland
| | - Carla Rohrer Bley
- Vetsuisse Faculty, Division of Radiation Oncology, University of Zurich, Winterthurerstr 258C, CH-8057, Zurich, Switzerland
| | - Angelika Schnieke
- Livestock Biotechnology, School of Live Sciences, Technische Universität München (TUM), Liesel-Beckmannstr 1, 85354, Freising, Germany
| | - Ann-Kathrin Samt
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Dennis Thölke
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Philipp Lennartz
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Melissa Schwab
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Fei Wang
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Ali Bashiri Dezfouli
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Gabriele Multhoff
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| |
Collapse
|
5
|
Salvermoser L, Flisikowski K, Dressel-Böhm S, Nytko KJ, Bley CR, Schnieke A, Samt AK, Thölke D, Lennartz P, Schwab M, Wang F, Dezfouli AB, Multhoff G. Correction to: Elevated circulating Hsp70 levels are correlative for malignancies in different mammalian species. Cell Stress Chaperones 2023; 28:119. [PMID: 36447096 PMCID: PMC9877251 DOI: 10.1007/s12192-022-01315-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- Lukas Salvermoser
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany.
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany.
- Department of Radiology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany.
| | - Krzysztof Flisikowski
- Livestock Biotechnology, School of Live Sciences, Technische Universität München (TUM), Liesel-Beckmannstr 1, 85354, Freising, Germany
| | - Susann Dressel-Böhm
- Vetsuisse Faculty, Division of Radiation Oncology, University of Zurich, Winterthurerstr 258C, CH-8057, Zurich, Switzerland
| | - Katarzyna J Nytko
- Vetsuisse Faculty, Division of Radiation Oncology, University of Zurich, Winterthurerstr 258C, CH-8057, Zurich, Switzerland
| | - Carla Rohrer Bley
- Vetsuisse Faculty, Division of Radiation Oncology, University of Zurich, Winterthurerstr 258C, CH-8057, Zurich, Switzerland
| | - Angelika Schnieke
- Livestock Biotechnology, School of Live Sciences, Technische Universität München (TUM), Liesel-Beckmannstr 1, 85354, Freising, Germany
| | - Ann-Kathrin Samt
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Dennis Thölke
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Philipp Lennartz
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Melissa Schwab
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Fei Wang
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Ali Bashiri Dezfouli
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| | - Gabriele Multhoff
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research Technische, Universität München (TranslaTUM), Technische Universität München (TUM), Klinikum Rechts Der IsarEinsteinstr 25, 81675, Munich, Germany
- Department of Radiation Oncology, Klinikum Rechts Der Isar, Technische Universität München (TUM), Ismaningerstr 22, 81675, Munich, Germany
| |
Collapse
|
6
|
Kobelt D, Gürgen D, Becker M, Dahlmann M, Flechsig S, Schaeffeler E, Büttner F, Schmees C, Bohnert R, Bedke J, Schwab M, Wendler J, Schostak M, Jandrig B, Walther W, Hofmann J. Establishment and characterization of a preclinical platform of subcutaneous renal cell carcinoma (RCC) patient-derived xenograft models to evaluate novel treatment strategies. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00834-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Schwab M, Pamminger M, Kremser C, Obmann D, Haltmeier M, Mayr A. Preliminary data on a fully automated left ventricular late gadolinium enhancement detection by a convolutional neuronal network in chronic myocardial infarction. Eur Heart J Cardiovasc Imaging 2022. [DOI: 10.1093/ehjci/jeac141.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): FWF- Der Wissenschaftsfonds
Aim
To compare a fully automated segmentation of left ventricular late gadolinium enhancement (LGE) as evaluated by a convolutional neuronal network (CNN) with manual segmentation in chronic myocardial infarction.
Methods
Cardiac magnetic resonance imaging including two-dimensional LGE imaging was performed in 191 patients on a 1.5 T clinical scanner 12 months after ST-elevation myocardial infarction. LGE images were presented to a trained CNN for automated determination of left ventricular myocardium and consequently absolute LGE volume. Manual LGE segmentation according to the +5-SD method was used as reference standard. Image quality was assessed according to a 3-point Likert scale (2 = perfect image quality, 1 = some artifacts witout impaired LGE delineation, 0 = strong artifacts with impaired LGE delineation). Regression and Bland-Altman analysis were performed.
Results
In 191 included patients (182 male, mean age 57 years) LGE volume was 9.7 [IQR 3.6 to 16.2] ml according to manual segmentation and 8.3 [3.2 to 17.6] ml according to CNN segmentation. Bland-Altman analysis showed little average difference (-0.5 ml, p=0.257), however, limits of agreement ranged from -18.4 ml to 17.5 ml. Linear correlation was fair (0.57, p<0.001). Subgroup analysis according to image quality showed comparable performance of CNN segmentation in all three groups.
Conclusion
Our fully automated LGE segmentation based on a CNN in two-dimensional data sets provides measurements with little average difference compared to very time-consuming manual segmentations. However, dispersion is substantially and limits the current application of this approach on a per-patient basis. Image quality does not affect CNN performance.
Collapse
Affiliation(s)
- M Schwab
- Medical University of Innsbruck , Innsbruck , Austria
| | - M Pamminger
- Medical University of Innsbruck , Innsbruck , Austria
| | - C Kremser
- Medical University of Innsbruck , Innsbruck , Austria
| | - D Obmann
- University of Innsbruck, Department of Mathematics , Innsbruck , Austria
| | - M Haltmeier
- University of Innsbruck, Department of Mathematics , Innsbruck , Austria
| | - A Mayr
- Medical University of Innsbruck , Innsbruck , Austria
| |
Collapse
|
8
|
Bedke J, Herrmann L, Stühler V, Winter S, Reustle A, Stenzl A, Schaeffeler E, Schwab M. Immunological markers and somatic mutations as predictors for therapy selection in metastatic renal cell carcinoma. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)00789-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
9
|
Staib C, Herbert S, Schwab M, Wöckel A, Häusler S. P-130 Morphokinetic analysis of early human embryo development and its relationship to endometriosis resection: a retrospective time-lapse study with the use of KIDScore D3 and D5. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Does complete resection of endometriosis improve embryo quality as assessed by morphokinetic parameters using time-lapse microscopy?
Summary answer
Complete resection of endometriosis in affected women undergoing assisted reproduction is shown to have a positive impact on embryo morphokinetic parameters represented in embryo quality.
What is known already
Endometriosis is one of the most common gynaecological diseases. It is characterized by the presence of cells comparable to those in the endometrium but being located outside of the uterine cavity. About 4-30% women of child-bearing age are affected by endometriosis. In vitro fertilization (IVF) studies have suggested that women with more advanced endometriosis have poor ovarian reserve, low oocyte and embryo quality and poor implantation rates. Moreover inflammatory peritoneal fluid shows a toxic effect on embryos. This might have an impact on morphokinetic timings but there is only limited data available concerning morphokinetics and endometriosis.
Study design, size, duration
246 embryos (endometriosis group: n = 85; non-endometriosis control group: n = 115; complete resection of endometriosis= 46) undergoing infertility treatment at our clinics were included in this retrospective study. Inclusion criteria were female patients aged between 18 and 45 years undergoing IVF and / or ICSI treatment. The in vitro culture was performed in a closed time-lapse incubator (EmbryoScope®, Vitrolife) up to day 3 or in a prolonged culture up to day 5.
Participants/materials, setting, methods
Patient treatment included conventional insemination or intracytoplasmatic sperm injection. IVF inseminated or ICSI injected oocytes were culturd in the TimeLapse monitoring incubator. Embryos were cultured for 3 to 5 days without media change at 6.8% CO2 and 5% O2 at 37°C. During embryo culture morphokinetic parameters and events were constantly annotated. Analysis was performed using the EmbryoViewer software and evaluated applying KIDScoreTM D3 or KIDScoreTM D5 according to the day of embryo transfer.
Main results and the role of chance
The analysis revealed a median KIDScoreTM D5 of 2.3 (on a scale from 1 to 9.9) for embryos from patients suffering from endometriosis without complete resection. The control group without endometriosis achieved a score of 7.0 (p = 0.001). The median for embryos from endometriosis patients with complete resection was 7.1 which meant a significant increase compared to embryos from patients without complete resection (p = 0.002).
Effect size according to Cohen showed a moderate up to strong biological effect (r = 0.4) for complete resection vs. no resection of endometriosis. For the three groups KIDScoreTM D3, pregnancy rates as well as abortion rates showed the same clinical trends.
Additionally, we could describe a series of four patients undergoing IVF-cycles before and after a complete resection of their endometriosis. As expected, in three out of four cases they showed a clear increase in their embryo quality after complete resection of endometriosis.
Limitations, reasons for caution
The main limitation of the study is the relative small sample size of the groups, especially the number of patients with endometriosis resection. Additionally, the study is limited to its retrospective design.
Wider implications of the findings
Pathogenesis of endometriosis related infertility is multifactorial and not completely understood. But knowing that endometrioid lesions produce inflammatory cytokines which are toxic for oocytes and embryos, resection of the lesions in order to reduce inflammation seems to be a plausible approach.
Trial registration number
20191007 01
Collapse
Affiliation(s)
- C Staib
- University of Würzburg, Zentrum für gynäkologische Endokrinologie und Reproduktionsmedizin , Wuerzburg, Germany
| | - S.L Herbert
- University of Würzburg, Zentrum für gynäkologische Endokrinologie und Reproduktionsmedizin , Wuerzburg, Germany
| | - M Schwab
- University of Würzburg, Zentrum für gynäkologische Endokrinologie und Reproduktionsmedizin , Wuerzburg, Germany
| | - A Wöckel
- University of Würzburg, Zentrum für gynäkologische Endokrinologie und Reproduktionsmedizin , Wuerzburg, Germany
| | - S Häusler
- Hospital St. Hedwig of The Order of St. John- University of Regensburg, University Department of Obstetrics and Gynecology , Regensburg, Germany
| |
Collapse
|
10
|
Bashiri Dezfouli A, Yazdi M, Benmebarek MR, Schwab M, Michaelides S, Miccichè A, Geerts D, Stangl S, Klapproth S, Wagner E, Kobold S, Multhoff G. CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells. Front Immunol 2022; 13:883694. [PMID: 35720311 PMCID: PMC9198541 DOI: 10.3389/fimmu.2022.883694] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Accepted: 05/02/2022] [Indexed: 11/25/2022] Open
Abstract
Strategies to boost anti-tumor immunity are urgently needed to treat therapy-resistant late-stage cancers, including colorectal cancers (CRCs). Cytokine stimulation and genetic modifications with chimeric antigen receptors (CAR) represent promising strategies to more specifically redirect anti-tumor activities of effector cells like natural killer (NK) and T cells. However, these approaches are critically dependent on tumor-specific antigens while circumventing the suppressive power of the solid tumor microenvironment and avoiding off-tumor toxicities. Previously, we have shown that the stress-inducible heat shock protein 70 (Hsp70) is frequently and specifically expressed on the cell surface of many different, highly aggressive tumors but not normal tissues. We could take advantage of tumors expressing Hsp70 on their membrane (‘mHsp70’) to attract and engage NK cells after in vitro stimulation with the 14-mer Hsp70 peptide TKDNNLLGRFELSG (TKD) plus low dose interleukin (IL)-2. However, a potential limitation of activated primary NK cells after adoptive transfer is their comparably short life span. T cells are typically long-lived but do not recognize mHsp70 on tumor cells, even after stimulation with TKD/IL-2. To combine the advantages of mHsp70-specificity with longevity, we constructed a CAR having specificity for mHsp70 and retrovirally transduced it into primary T cells. Co-culture of anti-Hsp70 CAR-transduced T cells with mHsp70-positive tumor cells stimulates their functional responsiveness. Herein, we demonstrated that human CRCs with a high mHsp70 expression similarly attract TKD/IL-2 stimulated NK cells and anti-Hsp70 CAR T cells, triggering the release of their lytic effector protein granzyme B (GrB) and the pro-inflammatory cytokine interferon (IFN)-γ, after 4 and 24 hours, respectively. In sum, stimulated NK cells and anti-Hsp70 CAR T cells demonstrated comparable anti-tumor effects, albeit with somewhat differing kinetics. These findings, together with the fact that mHsp70 is expressed on a large variety of different cancer entities, highlight the potential of TKD/IL-2 pre-stimulated NK, as well as anti-Hsp70 CAR T cells to provide a promising direction in the field of targeted, cell-based immunotherapies which can address significant unmet clinical needs in a wide range of cancer settings.
Collapse
Affiliation(s)
- Ali Bashiri Dezfouli
- Central Institute for Translational Cancer Research Technische Universität München (TranslaTUM), Department of Radiation Oncology, Klinikum rechts der Isar, Munich, Germany
| | - Mina Yazdi
- Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität (LMU), Munich, Germany
| | - Mohamed-Reda Benmebarek
- Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research Deutsches Zentrum für Lungenforschung (DZL), Munich, Germany
| | - Melissa Schwab
- Central Institute for Translational Cancer Research Technische Universität München (TranslaTUM), Department of Radiation Oncology, Klinikum rechts der Isar, Munich, Germany
| | - Stefanos Michaelides
- Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research Deutsches Zentrum für Lungenforschung (DZL), Munich, Germany
| | | | | | - Stefan Stangl
- Central Institute for Translational Cancer Research Technische Universität München (TranslaTUM), Department of Radiation Oncology, Klinikum rechts der Isar, Munich, Germany.,Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany
| | - Sarah Klapproth
- Institute of Experimental Hematology, Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany
| | - Ernst Wagner
- Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität (LMU), Munich, Germany
| | - Sebastian Kobold
- Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research Deutsches Zentrum für Lungenforschung (DZL), Munich, Germany.,German Center for Translational Cancer Research Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany
| | - Gabriele Multhoff
- Central Institute for Translational Cancer Research Technische Universität München (TranslaTUM), Department of Radiation Oncology, Klinikum rechts der Isar, Munich, Germany
| |
Collapse
|
11
|
Schwab M, Thunborg K, Azimzadeh O, von Toerne C, Shevtsov M, Zdralevic M, Pouyssegur J, Renner K, Kreutz M, Vaupel P, Multhoff G. Abstract 5426: Down-regulation of cancer metabolism enhances radiosensitivity by impairing the heat shock response. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-5426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Therapy (radiation) resistance can, inter alia, be caused by an increased lactate dehydrogenase (LDH) activity, elevated concentrations of the oncometabolite lactate and an overexpression of anti-apoptotic heat shock proteins (HSPs). In this study we aimed to break radioresistance by targeting the cancer metabolism. We could show, for the first time, that the lactate metabolism and heat shock response are co-regulated in two cancer cell systems (murine B16F10 melanoma cells, human LS174T colorectal adenocarcinoma cells). A CRISPR/Cas9 induced double knockout of LDHA/B (LDH−/−) as well as a pharmacological inhibition of LDH by Oxamate or GNE-140 reduces tumor growth, ROS production and synthesis of different HSPs, including Hsp90, Hsp70 and Hsp27. Moreover, the membrane Hsp70 density was significantly reduced on tumor cells after inhibition of the LDH activity as a consequence of a down-regulated lipid metabolism affecting the Hsp70-anchoring, tumor-specific glycosphingolipid Gb3. Our results demonstrate that influencing cancer metabolism increases radiation sensitivity by an impairment of the stress response. Since presently available LDH inhibitors have a low stability and high toxicity in vivo, we are currently investigating more potent LDH inhibitors with a beneficial safety profile. In summary, targeting the lactate metabolism provides a promising strategy to improve radiosensitivity by impairing the stress response.
Citation Format: Melissa Schwab, Katharina Thunborg, Omid Azimzadeh, Christine von Toerne, Maxim Shevtsov, Masa Zdralevic, Jacques Pouyssegur, Kathrin Renner, Marina Kreutz, Peter Vaupel, Gabriele Multhoff. Down-regulation of cancer metabolism enhances radiosensitivity by impairing the heat shock response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5426.
Collapse
|
12
|
Schwab M, Multhoff G. A Low Membrane Hsp70 Expression in Tumor Cells With Impaired Lactate Metabolism Mediates Radiosensitization by NVP-AUY922. Front Oncol 2022; 12:861266. [PMID: 35463341 PMCID: PMC9022188 DOI: 10.3389/fonc.2022.861266] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 03/15/2022] [Indexed: 11/13/2022] Open
Abstract
As overexpression and membrane localization of stress proteins together with high lactate levels promote radioresistance in tumor cells, we studied the effect of the Hsp90 inhibitor NVP-AUY922 on the cytosolic and membrane expression of heat shock proteins (HSPs) and radiosensitivity in murine melanoma (B16F10) and human colorectal (LS174T) wildtype (WT) and lactate dehydrogenases A/B double knockout (LDH−/−) tumor cells. Double knockout for LDHA/B has been found to reduce cytosolic as well as membrane HSP levels, whereas treatment with NVP-AUY922 stimulates the synthesis of Hsp27 and Hsp70, but does not affect membrane Hsp70 expression. Despite NVP-AUY922-inducing elevated levels of cytosolic HSP, radiosensitivity was significantly increased in WT cells and even more pronounced in LDH−/− cells. An impaired lipid metabolism in LDH−/− cells reduces the Hsp70 membrane-anchoring sphingolipid globotriaosylceramide (Gb3) and thereby results in a decreased Hsp70 cell surface density on tumor cells. Our results demonstrate that the membrane Hsp70 density, but not cytosolic HSP levels determines the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in LDH−/− cells.
Collapse
Affiliation(s)
- Melissa Schwab
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of Medicine, Klinikum Rechts der Isar, Technical University of Munich (TUM), Munich, Germany
| | - Gabriele Multhoff
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of Medicine, Klinikum Rechts der Isar, Technical University of Munich (TUM), Munich, Germany.,Department of Radiation Oncology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich (TUM), Munich, Germany
| |
Collapse
|
13
|
Stuehler V, Herrmann L, Winter S, Bohnert R, Reustle A, Hennenlotter J, Rausch S, Stenzl A, Schwab M, Schaeffeler E, Bedke J. Immunological markers and somatic mutations as predictors for therapy selection in metastatic renal cell carcinoma. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01197-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Stuehler V, Rausch S, Winter S, Schmees C, Maas M, Walz S, Stenzl A, Bedke J, Schwab M, Schaeffeler E. Autophagy as a new therapeutic pathway. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01192-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Franke K, Bublak P, Hoyer D, Billiet T, Gaser C, Witte OW, Schwab M. In vivo biomarkers of structural and functional brain development and aging in humans. Neurosci Biobehav Rev 2021; 117:142-164. [PMID: 33308708 DOI: 10.1016/j.neubiorev.2017.11.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 11/01/2017] [Accepted: 11/03/2017] [Indexed: 12/25/2022]
Abstract
Brain aging is a major determinant of aging. Along with the aging population, prevalence of neurodegenerative diseases is increasing, therewith placing economic and social burden on individuals and society. Individual rates of brain aging are shaped by genetics, epigenetics, and prenatal environmental. Biomarkers of biological brain aging are needed to predict individual trajectories of aging and the risk for age-associated neurological impairments for developing early preventive and interventional measures. We review current advances of in vivo biomarkers predicting individual brain age. Telomere length and epigenetic clock, two important biomarkers that are closely related to the mechanistic aging process, have only poor deterministic and predictive accuracy regarding individual brain aging due to their high intra- and interindividual variability. Phenotype-related biomarkers of global cognitive function and brain structure provide a much closer correlation to age at the individual level. During fetal and perinatal life, autonomic activity is a unique functional marker of brain development. The cognitive and structural biomarkers also boast high diagnostic specificity for determining individual risks for neurodegenerative diseases.
Collapse
Affiliation(s)
- K Franke
- Department of Neurology, Jena University Hospital, Jena, Germany.
| | - P Bublak
- Department of Neurology, Jena University Hospital, Jena, Germany
| | - D Hoyer
- Department of Neurology, Jena University Hospital, Jena, Germany
| | | | - C Gaser
- Department of Neurology, Jena University Hospital, Jena, Germany; Department of Psychiatry, Jena University Hospital, Jena, Germany
| | - O W Witte
- Department of Neurology, Jena University Hospital, Jena, Germany
| | - M Schwab
- Department of Neurology, Jena University Hospital, Jena, Germany
| |
Collapse
|
16
|
Chambel S, Oliveira R, Ferreira A, Antunes Lopes T, Schwab M, Cruz C. Sprouting of bladder afferents following spinal cord injury is independent from the lumbosacral cord highly repulsive environment. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)00405-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Lobinger D, Gempt J, Sievert W, Barz M, Schmitt S, Nguyen HT, Stangl S, Werner C, Wang F, Wu Z, Fan H, Zanth H, Shevtsov M, Pilz M, Riederer I, Schwab M, Schlegel J, Multhoff G. Potential Role of Hsp70 and Activated NK Cells for Prediction of Prognosis in Glioblastoma Patients. Front Mol Biosci 2021; 8:669366. [PMID: 34079819 PMCID: PMC8165168 DOI: 10.3389/fmolb.2021.669366] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 05/04/2021] [Indexed: 11/13/2022] Open
Abstract
Despite rapid progress in the treatment of many cancers, glioblastoma remains a devastating disease with dismal prognosis. The aim of this study was to identify chaperone- and immune-related biomarkers to improve prediction of outcome in glioblastoma. Depending on its intra- or extracellular localization the major stress-inducible heat shock protein 70 (Hsp70) fulfills different tasks. In the cytosol Hsp70 interferes with pro-apoptotic signaling pathways and thereby protects tumor cells from programmed cell death. Extracellular Hsp70 together with pro-inflammatory cytokines are reported to stimulate the expression of activatory NK cell receptors, recognizing highly aggressive human tumor cells that present Hsp70 on their cell surface. Therefore, intra-, extracellular and membrane-bound Hsp70 levels were assessed in gliomas together with activatory NK cell receptors. All gliomas were found to be membrane Hsp70-positive and high grade gliomas more frequently show an overexpression of Hsp70 in the nucleus and cytosol. Significantly elevated extracellular Hsp70 levels are detected in glioblastomas with large necrotic areas. Overall survival (OS) is more favorable in patients with low Hsp70 serum levels indicating that a high Hsp70 expression is associated with an unfavorable prognosis. The data provide a first hint that elevated frequencies of activated NK cells at diagnosis might be associated with a better clinical outcome.
Collapse
Affiliation(s)
- Dominik Lobinger
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Jens Gempt
- Department of Neurosurgery, School of Medicine, Technical University Munich (TUM), School of Medicine, Munich, Germany
| | - Wolfgang Sievert
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Melanie Barz
- Department of Neurosurgery, School of Medicine, Technical University Munich (TUM), School of Medicine, Munich, Germany
| | - Sven Schmitt
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Huyen Thie Nguyen
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Stefan Stangl
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Caroline Werner
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Fei Wang
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Zhiyuan Wu
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Hengyi Fan
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Hannah Zanth
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Maxim Shevtsov
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany.,Institute of Cytology of the Russian Academy of Sciences, St. Petersburg, Russia
| | - Mathias Pilz
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Isabelle Riederer
- Department of Neuroradiology, School of Medicine, Technical University Munich (TUM), Munich, Germany
| | - Melissa Schwab
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| | - Jürgen Schlegel
- Department of Neuropathology, Technical University Munich (TUM), Munich, Germany
| | - Gabriele Multhoff
- Department of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.,Central Institute for Translational Cancer Research, School of Medicine, Technical University Munich, Munich, Germany
| |
Collapse
|
18
|
Pattschull G, Walz S, Gründl M, Schwab M, Rühl E, Baluapuri A, Cindric-Vranesic A, Kneitz S, Wolf E, Ade CP, Rosenwald A, von Eyss B, Gaubatz S. The Myb-MuvB Complex Is Required for YAP-Dependent Transcription of Mitotic Genes. Cell Rep 2020; 27:3533-3546.e7. [PMID: 31216474 DOI: 10.1016/j.celrep.2019.05.071] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 04/18/2019] [Accepted: 05/17/2019] [Indexed: 02/06/2023] Open
Abstract
YAP and TAZ, downstream effectors of the Hippo pathway, are important regulators of proliferation. Here, we show that the ability of YAP to activate mitotic gene expression is dependent on the Myb-MuvB (MMB) complex, a master regulator of genes expressed in the G2/M phase of the cell cycle. By carrying out genome-wide expression and binding analyses, we found that YAP promotes binding of the MMB subunit B-MYB to the promoters of mitotic target genes. YAP binds to B-MYB and stimulates B-MYB chromatin association through distal enhancer elements that interact with MMB-regulated promoters through chromatin looping. The cooperation between YAP and B-MYB is critical for YAP-mediated entry into mitosis. Furthermore, the expression of genes coactivated by YAP and B-MYB is associated with poor survival of cancer patients. Our findings provide a molecular mechanism by which YAP and MMB regulate mitotic gene expression and suggest a link between two cancer-relevant signaling pathways.
Collapse
Affiliation(s)
- Grit Pattschull
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Wuerzburg, Wuerzburg 97074, Germany
| | - Susanne Walz
- Comprehensive Cancer Center Mainfranken, Core Unit Bioinformatics, Biocenter, University of Wuerzburg, Wuerzburg 97074, Germany
| | - Marco Gründl
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Wuerzburg, Wuerzburg 97074, Germany
| | - Melissa Schwab
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Wuerzburg, Wuerzburg 97074, Germany
| | - Eva Rühl
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Wuerzburg, Wuerzburg 97074, Germany
| | - Apoorva Baluapuri
- Cancer Systems Biology Group, Biochemistry and Molecular Biology, University of Wuerzburg, Wuerzburg 97074, Germany
| | | | - Susanne Kneitz
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Wuerzburg, Wuerzburg 97074, Germany
| | - Elmar Wolf
- Cancer Systems Biology Group, Biochemistry and Molecular Biology, University of Wuerzburg, Wuerzburg 97074, Germany
| | - Carsten P Ade
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Wuerzburg, Wuerzburg 97074, Germany
| | - Andreas Rosenwald
- Institute of Pathology and Comprehensive Cancer Center Mainfranken, University of Wuerzburg, Wuerzburg 97080, Germany
| | - Björn von Eyss
- Leibniz Institute on Aging, Fritz Lipmann Institute e.V., Jena 07745, Germany
| | - Stefan Gaubatz
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Wuerzburg, Wuerzburg 97074, Germany.
| |
Collapse
|
19
|
Chambel S, Oliveira R, Ferreira A, Vale L, Schwab M, Cruz C. Lumbosacral sprouting of bladder afferents after thoracic spinal cord injury reflects changes in levels of Nogo-A. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33032-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
20
|
Gründl M, Walz S, Hauf L, Schwab M, Werner KM, Spahr S, Schulte C, Maric HM, Ade CP, Gaubatz S. Interaction of YAP with the Myb-MuvB (MMB) complex defines a transcriptional program to promote the proliferation of cardiomyocytes. PLoS Genet 2020; 16:e1008818. [PMID: 32469866 PMCID: PMC7286521 DOI: 10.1371/journal.pgen.1008818] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 06/10/2020] [Accepted: 05/01/2020] [Indexed: 01/14/2023] Open
Abstract
The Hippo signalling pathway and its central effector YAP regulate proliferation of cardiomyocytes and growth of the heart. Using genetic models in mice we show that the increased proliferation of embryonal and postnatal cardiomyocytes due to loss of the Hippo-signaling component SAV1 depends on the Myb-MuvB (MMB) complex. Similarly, proliferation of postnatal cardiomyocytes induced by constitutive active YAP requires MMB. Genome studies revealed that YAP and MMB regulate an overlapping set of cell cycle genes in cardiomyocytes. Protein-protein interaction studies in cell lines and with recombinant proteins showed that YAP binds directly to B-MYB, a subunit of MMB, in a manner dependent on the YAP WW domains and a PPXY motif in B-MYB. Disruption of the interaction by overexpression of the YAP binding domain of B-MYB strongly inhibits the proliferation of cardiomyocytes. Our results point to MMB as a critical downstream effector of YAP in the control of cardiomyocyte proliferation. YAP, the major downstream transducer of the Hippo pathway, is a potent inducer of proliferation. Here we show that the Myb-MuvB complex (MMB) mediates cardiomyocyte proliferation by YAP. We find that YAP and MMB regulate an overlapping set of pro-proliferative genes which involves binding of MMB to the promoters of these genes. We also identified a direct interaction between the B-MYB subunit of MMB and YAP. Based on the binding studies, we created a tool called MY-COMP that interferes with the association YAP to B-MYB and strongly inhibits proliferation of cardiomyocytes. Together, our data suggests that the YAP-MMB interaction is essential for division of cardiomyocytes, underscoring the functional relevance of the crosstalk between these two pathways for proper heart development.
Collapse
Affiliation(s)
- Marco Gründl
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter University of Wuerzburg, Wuerzburg, Germany
| | - Susanne Walz
- Comprehensive Cancer Center Mainfranken, Core Unit Bioinformatics, Biocenter, University of Wuerzburg, Wuerzburg, Germany
| | - Laura Hauf
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter University of Wuerzburg, Wuerzburg, Germany
| | - Melissa Schwab
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter University of Wuerzburg, Wuerzburg, Germany
| | - Kerstin Marcela Werner
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter University of Wuerzburg, Wuerzburg, Germany
| | - Susanne Spahr
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter University of Wuerzburg, Wuerzburg, Germany
| | - Clemens Schulte
- Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Wuerzburg, Germany
| | - Hans Michael Maric
- Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Wuerzburg, Germany
| | - Carsten P. Ade
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter University of Wuerzburg, Wuerzburg, Germany
| | - Stefan Gaubatz
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter University of Wuerzburg, Wuerzburg, Germany
- * E-mail:
| |
Collapse
|
21
|
Fellinger H, Stangl S, Hernandez Schnelzer A, Schwab M, Di Genio T, Pieper M, Werner C, Shevtsov M, Haller B, Multhoff G. Time- and Dose-Dependent Effects of Ionizing Irradiation on the Membrane Expression of Hsp70 on Glioma Cells. Cells 2020; 9:cells9040912. [PMID: 32276468 PMCID: PMC7226755 DOI: 10.3390/cells9040912] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 04/06/2020] [Accepted: 04/07/2020] [Indexed: 12/20/2022] Open
Abstract
The major stress-inducible protein Hsp70 (HSPA1A) is overexpressed in the cytosol of many highly aggressive tumor cells including glioblastoma multiforme and presented on their plasma membrane. Depending on its intracellular or membrane localization, Hsp70 either promotes tumor growth or serves as a target for natural killer (NK) cells. The kinetics of the membrane Hsp70 (mHsp70) density on human glioma cells (U87) was studied after different irradiation doses to define the optimal therapeutic window for Hsp70-targeting NK cells. To maintain the cells in the exponential growth phase during a cultivation period of 7 days, different initial cell counts were seeded. Although cytosolic Hsp70 levels remained unchanged on days 4 and 7 after a sublethal irradiation with 2, 4 and 6 Gy, a dose of 2 Gy resulted in an upregulated mHsp70 density in U87 cells which peaked on day 4 and started to decline on day 7. Higher radiation doses (4 Gy, 6 Gy) resulted in an earlier and more rapid onset of the mHsp70 expression on days 2 and 1, respectively, followed by a decline on day 5. Membrane Hsp70 levels were higher on cells in G2/M than in G1; however, an irradiation-induced cell cycle arrest on days 4 and 7 was not associated with an increase in the mHsp70 density. Extracellular Hsp70 concentrations in the supernatant of irradiated cells were significantly higher than sham (0 Gy) irradiated cells on days 4 and 7, but not on day 1. Functionally, elevated mHsp70 densities were associated with a significantly better lysis by Hsp70-targeting NK cells. In summary, the kinetics of changes in the mHsp70 density upon irradiation on tumor cells is time- and dose-dependent.
Collapse
Affiliation(s)
- Helena Fellinger
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
| | - Stefan Stangl
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
| | - Alicia Hernandez Schnelzer
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
| | - Melissa Schwab
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
| | - Tommaso Di Genio
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
| | - Marija Pieper
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
| | - Caroline Werner
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
| | - Maxim Shevtsov
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
- Institute of the Russian Academy of Sciences (RAS), 194064 St. Petersburg, Russia
- Department of Biotechnology, Pavlov First Saint Petersburg State Medical University, 197022 St. Petersburg, Russia
| | - Bernhard Haller
- Institute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich (TUM), 81675 Munich, Germany;
| | - Gabriele Multhoff
- Radiation Immuno-Oncology Group, Center for Translational Cancer Research (TranslaTUM), School of medicine, Technical University of Munich (TUM), 81675 Munich, Germany; (H.F.); (S.S.); (A.H.S.); (M.S.); (T.D.G.); (M.P.); (C.W.); (M.S.)
- Department of Radiation Oncology, School of Medicine, Technical University of Munich (TUM), 81675 Munich, Germany
- Correspondence: ; Tel.: +49-89-4140-4514
| |
Collapse
|
22
|
Groga-Bada P, Heller F, Lente N, Hack L, Schaeffeler E, Winter S, Mueller K, Droppa M, Stimpfle F, Schwab M, Gawaz M, Geisler T, Rath D. P3641Matrix Metalloproteinase-2 polymorphisms are associated with prognosis of patients with symptomatic coronary artery disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Matrix Metalloproteinase-2 (MMP-2) is involved in regulation and proliferation of vascular and endothelial cells and is therefore an important component of atherosclerotic vessels. Inhibition of MMP-2 activity is associated with improvement of cardiac function in animal models after myocardial infarction. MMP-2 single nucleotide polymorphisms (SNPs) might alter MMP-2 expression and therefore influence prognosis in patients with symptomatic coronary artery disease (CAD).
Methods and results
Genotyping for selected MMP-2 SNPs variants (rs2241145, rs2285053, rs2287076, rs243865, rs7201) was performed in 943 consecutive patients with symptomatic CAD. All patients were followed-up for all-cause death (ACD), myocardial infarction (MI) and ischemic stroke (IS) for 360 days. The primary combined endpoint (CE) consisted of either first occurrence of ACD, and/or MI, and/or IS. Secondary endpoints were defined as the single events of ACD or MI. Homozygous carriers of major allele (rs2241145, rs2287076) showed significantly better event-free survival than carriers of the minor allele for CE (Log rank = 0.022 and Log rank= 0.015, respectively). Furthermore, homozygous carriers of major allele (rs2241145, rs2285053, rs2287076) showed significantly better event-free survival for ACD (Log rank= 0.047, Log rank= 0.006 and Log rank= 0.023, respectively). In multivariate analysis, MMP-2 rs2241145, rs2287076 and rs2285053 were significantly and independently associated with CE and ACD.
Figure 1
Conclusions
MMP-2 rs2241145, rs2287076 and rs2285053 are associated with prognosis and might be valuable for further risk stratification in CAD patients.
Acknowledgement/Funding
DFG, KFO 274, CRC TR 240
Collapse
Affiliation(s)
- P Groga-Bada
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - F Heller
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - N Lente
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - L Hack
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - E Schaeffeler
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - S Winter
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - K Mueller
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - M Droppa
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - F Stimpfle
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - M Schwab
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - M Gawaz
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - T Geisler
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - D Rath
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| |
Collapse
|
23
|
Rath D, Altgelt K, Mueller K, Hack LP, Schaeffeler E, Winter S, Schwab M, Chatterjee M, Gawaz M, Geisler T. P3643Junctional Adhesion Molecule-A (JAM-A) polymorphisms influence serum levels of soluble JAM-A and are associated with long term prognosis in coronary artery disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aims
Junctional adhesion molecule A (JAM-A/F11R) is a cell adhesion molecule. Membrane associated JAM-A mediates platelet aggregation, secretion, adhesion, and spreading. Plasma levels of JAM-A are elevated in hypertension and atherosclerosis. This study was designed to investigate the impact of JAM-A single nucleotide polymorphisms (SNPs) on circulatory JAM-A levels and prognosis in patients with symptomatic coronary artery disease (CAD).
Methods and results
JAM-A SNP analysis (JAM-A F11R rs2774276 and rs790056) was performed in 943 patients with symptomatic CAD. All patients were tracked for all-cause death (ACD), myocardial infarction (MI), and ischemic stroke (IS) for 1080 days. The primary combined endpoint (CE) was defined as a composite of ACD and/or MI and/or IS. Secondary endpoints were defined as the single events of ACD and MI. Homozygote carriers of the minor allele (F11R rs2774276 and rs790056) showed significantly worse event-free survival for MI when compared with major allele carriers (Log rank = 0.011 and log rank = 0.031, respectively). No significant differences could be shown for the CE and ACD. Of note, in multivariate analysis, both SNPs were significantly and independently associated with MI. Furthermore, serum levels of soluble JAM-A were elevated in homozygote carriers of minor allele when compared to major allele carriers. Finally, serum levels of soluble JAM-A were significantly elevated in patients with MI when compared to stable CAD (p=0.036).
Figure 1
Conclusion
JAM-A SNPs are associated with prognosis in patients with symptomatic coronary artery disease. Furthermore, JAM-A SNPs might influence serum concentration of soluble JAM-A. Finally, serum concentration of soluble JAM-A is higher in patients with myocardial infarction when compared to stable coronary artery disease. These findings suggest JAM-A as a valuable biomarker for risk stratification and tailoring therapies in patients with coronary artery disease.
Acknowledgement/Funding
DFG-KFO274, CRC/Transregio 240
Collapse
Affiliation(s)
- D Rath
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - K Altgelt
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - K Mueller
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - L P Hack
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - E Schaeffeler
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - S Winter
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - M Schwab
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - M Chatterjee
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - M Gawaz
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| | - T Geisler
- University hospital Tuebingen, Cardiology department, Tuebingen, Germany
| |
Collapse
|
24
|
Trimarchi H, Duboscq C, Genoud V, Lombi F, Muryan A, Young P, Schwab M, Castañón M, Rodríguez-Reimundes E, Forrester M, Pereyra H, Campolo-Girard V, Seminario O, Alonso M, Kordich L. Plasminogen Activator Inhibitor-1 Activity and 4G/5G Polymorphism in Hemodialysis. J Vasc Access 2018. [DOI: 10.1177/112972980800900212] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Introduction Chronic insufficiency alters homeostasis, in part due to endothelial inflammation. Plasminogen activator inhibitor-1 (PAI-1) is increased in renal disease, contributing to vascular damage. We assessed PAI-1 activity and PAI-1 4G/5G polymorphism in hemodialysis (HD) subjects and any association between thrombotic vascular access (VA) events and PAI-1 polymorphism. Methods Prospective, observational study in 36 HD patients: mean age: 66.6 ± 12.5 yr, males n=26 (72%), time on HD: 28.71 ± 22.45 months. Vascular accesses: 10 polytetrafluoroethylene grafts (PTFEG), 22 arteriovenous fistulae (AVF), four dual lumen catheters (CAT). Control group (CG): 40 subjects; mean age: 60.0 ± 15 yrs, males n=30 (75%). Group A (GA): thrombotic events (n=12), and group B (GB): No events (n=24). Groups were no different according to age (69.2 ± 9.12 vs. 65.3 ± 14.5 yrs), gender (males: 7; 58.3% vs. 18; 81.8%), time on HD (26.1 ± 14.7 vs. 30.1 ± 38.7 months), causes of renal failure. Time to follow-up for access thrombosis: 12 months. Results PAI-1 levels in HD: 7.21 ± 2.13 vs. CG: 0.42 ± 0.27 U/ml (p<0.0001). PAI-1 4G/5G polymorphic variant distribution in HD: 5G/5G: 6 (17%), 4G/5G: 23 (64%); 4G/4G: 7 (19%) and in CG: 5G/5G: 14 (35%); 4G/5G: 18 (45%); 4G/4G: 8 (20%). C-reactive protein (CRP) in HD: 24.5 ± 15.2 mg/L vs. in CG 2.3 ± 0.2 mg/L (p<0.0001). PAI-1 4G/5G variants: GA: 5G/5G: 3; 4G/5G: 8; 4G/4G: 1; GB: 5G/5G: 3; 4G/5G: 15; 4G/4G: 6. Thrombosis occurred in 8/10 patients (80%) with PTFEG, 3/22 (9%) in AVF, and 1/4 (25%) in CAT. Among the eight PTFEG patients with thrombosis, seven were PAI 4G/5G. Conclusions PAI-1 levels were elevated in HD patients, independent of their polymorphic variants, 4G/5G being the most prevalent variant. Our data suggest that in patients with PTFEG the 4G/5G variant might be associated with an increased thrombosis risk.
Collapse
Affiliation(s)
- H. Trimarchi
- Nephrology Unit, British Hospital of Buenos Aires
| | - C. Duboscq
- Hematology Unit, British Hospital of Buenos Aires
| | - V. Genoud
- Hemostasis and Thrombosis Laboratory, Department of Biological Chemistry, Faculty of Exact and Natural Sciences, University of Buenos Aires
| | - F. Lombi
- Nephrology Unit, British Hospital of Buenos Aires
| | - A. Muryan
- Biochemistry Unit, British Hospital of Buenos Aires
| | - P. Young
- Clinical Medicine Unit, British Hospital of Buenos Aires, Buenos Aires - Argentina
| | - M. Schwab
- Department of Internal Medicine, Lausanne University Hospital, Lausanne - Switzerland
| | - M. Castañón
- Hemostasis and Thrombosis Laboratory, Department of Biological Chemistry, Faculty of Exact and Natural Sciences, University of Buenos Aires
| | | | - M. Forrester
- Nephrology Unit, British Hospital of Buenos Aires
| | - H. Pereyra
- Nephrology Unit, British Hospital of Buenos Aires
| | | | - O. Seminario
- Nephrology Unit, British Hospital of Buenos Aires
| | - M. Alonso
- Clinical Medicine Unit, British Hospital of Buenos Aires, Buenos Aires - Argentina
| | - L. Kordich
- Hemostasis and Thrombosis Laboratory, Department of Biological Chemistry, Faculty of Exact and Natural Sciences, University of Buenos Aires
| |
Collapse
|
25
|
Danesi R, Del Re M, Ciccolini J, Schellens JHM, Schwab M, van Schaik RHN, van Kuilenburg ABP. Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? Ann Oncol 2018; 28:183. [PMID: 27687313 DOI: 10.1093/annonc/mdw448] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- R Danesi
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - M Del Re
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - J Ciccolini
- Clinical Pharmacokinetics, La Timone University Hospital, Marseille, and GPCO-Unicancer, Paris, France
| | - J H M Schellens
- Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M Schwab
- Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany
| | - R H N van Schaik
- IFCC Reference center - Pharmacogenetics, Department of Clinical Chemistry, Erasmus University, Rotterdam
| | - A B P van Kuilenburg
- Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
26
|
Lunkenheimer P, Emmert S, Gulich R, Köhler M, Wolf M, Schwab M, Loidl A. Electromagnetic-radiation absorption by water. Phys Rev E 2017; 96:062607. [PMID: 29347319 DOI: 10.1103/physreve.96.062607] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Indexed: 06/07/2023]
Abstract
Why does a microwave oven work? How does biological tissue absorb electromagnetic radiation? Astonishingly, we do not have a definite answer to these simple questions because the microscopic processes governing the absorption of electromagnetic waves by water are largely unclarified. This absorption can be quantified by dielectric loss spectra, which reveal a huge peak at a frequency of the exciting electric field of about 20 GHz and a gradual tailing off toward higher frequencies. The microscopic interpretation of such spectra is highly controversial and various superpositions of relaxation and resonance processes ascribed to single-molecule or molecule-cluster motions have been proposed for their analysis. By combining dielectric, microwave, THz, and far-infrared spectroscopy, here we provide nearly continuous temperature-dependent broadband spectra of water. Moreover, we find that corresponding spectra for aqueous solutions reveal the same features as pure water. However, in contrast to the latter, crystallization in these solutions can be avoided by supercooling. As different spectral contributions tend to disentangle at low temperatures, this enables us to deconvolute them when approaching the glass transition under cooling. We find that the overall spectral development, including the 20 GHz feature (employed for microwave heating), closely resembles the behavior known for common supercooled liquids. Thus water's absorption of electromagnetic waves at room temperature is not unusual but very similar to that of glass-forming liquids at elevated temperatures, deep in the low-viscosity liquid regime, and should be interpreted along similar lines.
Collapse
Affiliation(s)
- P Lunkenheimer
- Experimental Physics V, Center for Electronic Correlations and Magnetism, University of Augsburg, 86159 Augsburg, Germany
| | - S Emmert
- Experimental Physics V, Center for Electronic Correlations and Magnetism, University of Augsburg, 86159 Augsburg, Germany
| | - R Gulich
- Experimental Physics V, Center for Electronic Correlations and Magnetism, University of Augsburg, 86159 Augsburg, Germany
| | - M Köhler
- Experimental Physics V, Center for Electronic Correlations and Magnetism, University of Augsburg, 86159 Augsburg, Germany
| | - M Wolf
- Experimental Physics V, Center for Electronic Correlations and Magnetism, University of Augsburg, 86159 Augsburg, Germany
| | - M Schwab
- Experimental Physics V, Center for Electronic Correlations and Magnetism, University of Augsburg, 86159 Augsburg, Germany
| | - A Loidl
- Experimental Physics V, Center for Electronic Correlations and Magnetism, University of Augsburg, 86159 Augsburg, Germany
| |
Collapse
|
27
|
Schwab M, Fisel P, Schäffeler E. [Metabolomics and Cancer]. Pathologe 2017; 38:202-204. [PMID: 29138896 DOI: 10.1007/s00292-017-0374-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Affiliation(s)
- M Schwab
- Dr. Margarete Fischer-Bosch-Institut für klinische Pharmakologie, und Universität Tübingen, Auerbachstr. 112, 70376, Stuttgart, Deutschland.
- Abteilung klinische Pharmakologie, Universitätsklinikum Tübingen, Eberhard-Karls Universität Tübingen, Tübingen, Deutschland.
| | - P Fisel
- Dr. Margarete Fischer-Bosch-Institut für klinische Pharmakologie, und Universität Tübingen, Auerbachstr. 112, 70376, Stuttgart, Deutschland
| | - E Schäffeler
- Dr. Margarete Fischer-Bosch-Institut für klinische Pharmakologie, und Universität Tübingen, Auerbachstr. 112, 70376, Stuttgart, Deutschland
| |
Collapse
|
28
|
Nikolaus S, Schreiber S, Siegmund B, Bokemeyer B, Bästlein E, Bachmann O, Görlich D, Hofmann U, Schwab M, Kruis W. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence. J Crohns Colitis 2017; 11:1052-1062. [PMID: 28486634 DOI: 10.1093/ecco-jcc/jjx062] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 05/08/2017] [Indexed: 12/21/2022]
Abstract
BACKGROUND AND AIM Recent observational studies document that non-adherence to mesalamine therapy during remission is frequent. We aimed to investigate patient impact of patient education using objective assessments of adherence. METHODS A 14-month randomised, prospective clinical trial of adherence to mesalamine was conducted in 248 patients with ulcerative colitis [UC], Colitis Activity Index [CAI] ≤ 9, receiving standard care [n = 122] versus a standardised patient education programme [n = 126]. Primary endpoint was adherence at all visits (5-aminosalicylic acid [5-ASA] urine levels). Secondary endpoints included quality of life (inflammatory bowel disease questionnaise [IBDQ]), disease activity, partial adherence, and self-assessment of adherence. RESULTS Patient allocation was well balanced. Baseline non-adherence was high in quiescent/mildly active UC [52.4%] without difference between the groups (52.4% of patients in the education group versus 52.5% in the standard care group [p = 0.99]). No difference between the intervention group and standard care was seen in IBDQ, partial adherence, self-assessment of adherence, or therapy satisfaction at all visits. We suggest a model in which individual risks for non-adherence are driven by patients with young age, short disease duration, and low education levels. CONCLUSIONS Non-adherence is frequent in a population with quiescent/mildly active UC. Although more than 25% of the population was not in remission at the various time points, no relationship between disease activity and adherence was seen over the 14-month observation period. Physicians should maximise their efforts to motivate high-risk patients for adherence. Future trials should use objective exposure assessments to examine the impact of continuous education and consultations on the background of individual risks to develop non-adherence.
Collapse
Affiliation(s)
- S Nikolaus
- Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Germany
| | - S Schreiber
- Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Germany
| | - B Siegmund
- Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - B Bokemeyer
- Gastroenterologische Schwerpunktpraxis, Minden, Germany
| | | | - O Bachmann
- Medizinische Hochschule Hannover, Hannover, Germany
| | - D Görlich
- Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - U Hofmann
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Tübingen,Germany
| | - M Schwab
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Tübingen, Germany.,Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany
| | - W Kruis
- Evangelisches Krankenhaus Kalk, Köln, Germany
| |
Collapse
|
29
|
Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, van de Graaf SFJ, Meyer MR, Maurer HH, Meier K, Weiss J, Bruckner T, Alexandrov A, Urban S, Mikus G, Haefeli WE. The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics. Clin Pharmacol Ther 2017; 103:341-348. [DOI: 10.1002/cpt.744] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 05/10/2017] [Accepted: 05/13/2017] [Indexed: 12/26/2022]
Affiliation(s)
- A Blank
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - A Eidam
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - M Haag
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology; University of Tübingen; Stuttgart Germany
- German Center for Infection Research (DZIF); Tübingen Partner Site; Tübingen Germany
| | - N Hohmann
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - J Burhenne
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - M Schwab
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology; University of Tübingen; Stuttgart Germany
- German Center for Infection Research (DZIF); Tübingen Partner Site; Tübingen Germany
- Department of Clinical Pharmacology; University Hospital Tübingen; Tübingen Germany
- Department of Pharmacy and Biochemistry; University of Tübingen; Tübingen Germany
| | - SFJ van de Graaf
- Tytgat Institute for Liver and Intestinal Research & Department of Gastroenterology & Hepatology; Academic Medical Center; Amsterdam The Netherlands
| | - MR Meyer
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- Experimental and Clinical Toxicology; Saarland University; Homburg Germany
| | - HH Maurer
- Experimental and Clinical Toxicology; Saarland University; Homburg Germany
| | - K Meier
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - J Weiss
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - T Bruckner
- Institute of Medical Biostatistics and Medical Informatics; Heidelberg University Hospital; Heidelberg Germany
| | | | - S Urban
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
- Department of Infectious Diseases, Molecular Virology; Heidelberg University Hospital; Heidelberg Germany
| | - G Mikus
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - WE Haefeli
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| |
Collapse
|
30
|
van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ. CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther 2017; 102:152. [PMID: 30239993 DOI: 10.1002/cpt.725] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
31
|
Anegroaie P, Frasch MG, Rupprecht S, Antonow-Schlorke I, Müller T, Schubert H, Witte OW, Schwab M. Development of somatosensory-evoked potentials in foetal sheep: effects of betamethasone. Acta Physiol (Oxf) 2017; 220:137-149. [PMID: 27580709 DOI: 10.1111/apha.12795] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2016] [Revised: 06/15/2016] [Accepted: 08/30/2016] [Indexed: 11/30/2022]
Abstract
AIM Antenatal glucocorticoids are used to accelerate foetal lung maturation in babies threatened with premature labour. We examined the influence of glucocorticoids on functional and structural maturation of the central somatosensory pathway in foetal sheep. Somatosensory-evoked potentials (SEP) reflect processing of somatosensory stimuli. SEP latencies are determined by afferent stimuli transmission while SEP amplitudes reveal cerebral processing. METHODS After chronic instrumentation of foetal sheep, mothers received saline (n = 9) or three courses of betamethasone (human equivalent dose of 2 × 110 μg kg-1 betamethasone i.m. 24 h apart, n = 12) at 0.7, 0.75 and 0.8 of gestational age. Trigeminal SEP were evoked prior to, 4 and 24 h after each injection and at 0.8 of gestational age before brains were histologically processed. RESULTS Somatosensory-evoked potentials were already detectable at 0.7 of gestation age. The early and late responses N20 and N200 were the only reproducible peaks over the entire study period. With advancing gestational age, SEP latencies decreased but amplitudes remained unchanged. Acutely, betamethasone did not affect SEP latencies and amplitudes 4 and 24 h following administration. Chronically, betamethasone delayed developmental decrease in the N200 but not N20 latency by 2 weeks without affecting amplitudes. In parallel, betamethasone decreased subcortical white matter myelination but did not affect network formation and synaptic density in the somatosensory cortex. CONCLUSION Somatosensory stimuli are already processed by the foetal cerebral cortex at the beginning of the third trimester. Subsequent developmental decrease in SEP latencies suggests ongoing maturation of afferent sensory transmission. Antenatal glucocorticoids affect structural and functional development of the somatosensory system with specific effects at subcortical level.
Collapse
Affiliation(s)
- P. Anegroaie
- Department of Neurology; Jena University Hospital; Jena Germany
- Department of Pediatric Surgery; Jena University Hospital; Jena Germany
| | - M. G. Frasch
- Department of Obstetrics and Gynecology; University of Washington; Seattle WA USA
| | - S. Rupprecht
- Department of Neurology; Jena University Hospital; Jena Germany
| | | | - T. Müller
- Institute of Laboratory Animal Science; Jena University Hospital; Jena Germany
| | - H. Schubert
- Institute of Laboratory Animal Science; Jena University Hospital; Jena Germany
| | - O. W. Witte
- Department of Neurology; Jena University Hospital; Jena Germany
| | - M. Schwab
- Department of Neurology; Jena University Hospital; Jena Germany
| |
Collapse
|
32
|
Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez J, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 2017; 102:213-218. [PMID: 28002639 DOI: 10.1002/cpt.598] [Citation(s) in RCA: 123] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Accepted: 12/07/2016] [Indexed: 12/16/2022]
Affiliation(s)
- G C Bell
- Personalized Medicine Program, Mission Health, Asheville, North Carolina, USA
| | - K E Caudle
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - M Whirl-Carrillo
- Department of Genetics, Stanford University, Stanford, California, USA
| | - R J Gordon
- University of California, San Diego, Department of Anesthesiology, San Diego, California, USA
| | - K Hikino
- Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois, USA
| | - C A Prows
- Division of Human Genetics, Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - A Gaedigk
- Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy-Kansas City, Kansas City, Missouri, USA
| | - Jag Agundez
- Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA.,Department of Pharmacology, University of Extremadura, Cáceres, Spain
| | - S Sadhasivam
- Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.,Department of Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - T E Klein
- Department of Genetics, Stanford University, Stanford, California, USA
| | - M Schwab
- Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tübingen, Germany.,Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.,Department of Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany
| |
Collapse
|
33
|
Kuo AH, Li J, Li C, Huber HF, Schwab M, Nathanielsz PW, Clarke GD. Prenatal steroid administration leads to adult pericardial and hepatic steatosis in male baboons. Int J Obes (Lond) 2017; 41:1299-1302. [PMID: 28337030 PMCID: PMC5548625 DOI: 10.1038/ijo.2017.82] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2017] [Revised: 02/18/2017] [Accepted: 03/15/2017] [Indexed: 11/18/2022]
Abstract
Developmental programming studies indicate that glucocorticoids modify
fetal development. We hypothesized that administration of the synthetic
glucocorticoid (sGC) betamethasone to pregnant baboons at doses and stages of
fetal life equivalent to human obstetric practice to decrease premature
offspring morbidity and mortality, programs lipid metabolism. In 10-year-old
male baboons (human equivalent 40) exposed in fetal life to betamethasone or
saline, we quantified pericardial fat and hepatic lipid content with magnetic
resonance imaging and spectroscopy. sGC offspring delivered at term as do most
sGC exposed human neonates. Pericardial fat thickness (7.7 ± 3.6 mm vs.
3.1 ± 1.1 mm, M ± SD; p = 0.022; n=5) and
hepatic fatty acids (13.3 ± 11.0 % vs. 2.5 ± 2.2
%; p = 0.046; n=5) increased following sGC without birth
weight or current body morphometric differences. Our results indicate that
antenatal sGC therapy caused abnormal fat deposition and adult body composition
in mid-life primate offspring. The concern raised is that this degree of
pericardial and hepatic lipid accumulation can lead to harmful local
lipotoxicity. In summary, developmental programing by sGC produces a mid-life
metabolically obese but normal weight phenotype. Prior studies show sexually
dimorphic responses to some programming challenges thus female studies are
necessary.
Collapse
Affiliation(s)
- A H Kuo
- Department of Radiology and Research Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - J Li
- Xiangya School of Medicine, Central South University, Changsha, Hunan, China.,Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - C Li
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.,Department of Animal Science, University of Wyoming, Laramie, WY, USA
| | - H F Huber
- Department of Animal Science, University of Wyoming, Laramie, WY, USA
| | - M Schwab
- Department of Neurology, Jena University Hospital, Jena, Germany
| | - P W Nathanielsz
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.,Department of Animal Science, University of Wyoming, Laramie, WY, USA
| | - G D Clarke
- Department of Radiology and Research Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.,Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| |
Collapse
|
34
|
van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther 2017; 101:341-358. [DOI: 10.1002/cpt.602] [Citation(s) in RCA: 186] [Impact Index Per Article: 26.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Revised: 12/12/2016] [Accepted: 12/13/2016] [Indexed: 12/14/2022]
Affiliation(s)
- CH van der Wouden
- Department of Clinical Pharmacy and Toxicology; Leiden University Medical Center; Leiden The Netherlands
| | - A Cambon-Thomsen
- UMR Inserm U1027 and Université de Toulouse III Paul Sabatier; Toulouse France
| | - E Cecchin
- Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico; National Cancer Institute; Aviano Italy
| | - KC Cheung
- Royal Dutch Pharmacists Association (KNMP); The Hague The Netherlands
| | - CL Dávila-Fajardo
- Department of Clinical Pharmacy, Granada University Hospital; Institute for Biomedical Research; Granada Spain
| | - VH Deneer
- Department of Clinical Pharmacy; St Antonius Hospital; Nieuwegein The Netherlands
| | - V Dolžan
- Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine; University of Ljubljana; Slovenia
| | - M Ingelman-Sundberg
- Department of Physiology and Pharmacology, Section of Pharmacogenetics; Karolinska Institutet; Stockholm Sweden
| | - S Jönsson
- Department of Pharmaceutical Biosciences; Uppsala University; Uppsala Sweden
| | - MO Karlsson
- Department of Pharmaceutical Biosciences; Uppsala University; Uppsala Sweden
| | - M Kriek
- Center for Clinical Genetics; Leiden University Medical Center; Leiden The Netherlands
| | | | - GP Patrinos
- University of Patras, School of Health Sciences, Department of Pharmacy; University Campus; Rion Patras Greece
| | - M Pirmohamed
- Department of Molecular and Clinical Pharmacology; Royal Liverpool University Hospital and University of Liverpool; Liverpool United Kingdom
| | - M Samwald
- Center for Medical Statistics, Informatics, and Intelligent Systems; Medical University of Vienna; Vienna Austria
| | - E Schaeffeler
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Germany and University of Tübingen; Tübingen Germany
| | - M Schwab
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart; Germany and University of Tübingen; Tübingen Germany
- Department of Clinical Pharmacology; University Hospital Tübingen; Tübingen Germany
- Department of Pharmacy and Biochemistry; University of Tübingen; Tübingen Germany
| | - D Steinberger
- Bio.logis Center for Human Genetics; Frankfurt am Main Germany
| | - J Stingl
- Research Division; Federal Institute for Drugs and Medical Devices; Bonn Germany
| | - G Sunder-Plassmann
- Division of Nephrology and Dialysis, Department of Internal Medicine III; Medical University of Vienna; Vienna Austria
| | - G Toffoli
- Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico; National Cancer Institute; Aviano Italy
| | - RM Turner
- Department of Molecular and Clinical Pharmacology; Royal Liverpool University Hospital and University of Liverpool; Liverpool United Kingdom
| | - MH van Rhenen
- Royal Dutch Pharmacists Association (KNMP); The Hague The Netherlands
| | - JJ Swen
- Department of Clinical Pharmacy and Toxicology; Leiden University Medical Center; Leiden The Netherlands
| | - H-J Guchelaar
- Department of Clinical Pharmacy and Toxicology; Leiden University Medical Center; Leiden The Netherlands
| | | |
Collapse
|
35
|
Tamm R, Mägi R, Tremmel R, Winter S, Mihailov E, Smid A, Möricke A, Klein K, Schrappe M, Stanulla M, Houlston R, Weinshilboum R, Mlinarič Raščan I, Metspalu A, Milani L, Schwab M, Schaeffeler E. Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies. Clin Pharmacol Ther 2017; 101:684-695. [PMID: 27770449 DOI: 10.1002/cpt.540] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 09/02/2016] [Accepted: 10/17/2016] [Indexed: 12/20/2022]
Abstract
Thiopurine-related hematotoxicity in pediatric acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases has been linked to genetically defined variability in thiopurine S-methyltransferase (TPMT) activity. While gene testing of TPMT is being clinically implemented, it is unclear if additional genetic variation influences TPMT activity with consequences for thiopurine-related toxicity. To examine this possibility, we performed a genome-wide association study (GWAS) of red blood cell TPMT activity in 844 Estonian individuals and 245 pediatric ALL cases. Additionally, we correlated genome-wide genotypes to human hepatic TPMT activity in 123 samples. Only genetic variants mapping to chromosome 6, including the TPMT gene region, were significantly associated with TPMT activity (P < 5.0 × 10-8 ) in each of the three GWAS and a joint meta-analysis of 1,212 cases (top hit P = 1.2 × 10-72 ). This finding is consistent with TPMT genotype being the primary determinant of TPMT activity, reinforcing the rationale for genetic testing of TPMT alleles in routine clinical practice to individualize mercaptopurine dosage.
Collapse
Affiliation(s)
- R Tamm
- Department of Biotechnology, Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia.,Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - R Mägi
- Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - R Tremmel
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tuebingen, Germany
| | - S Winter
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tuebingen, Germany
| | - E Mihailov
- Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - A Smid
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| | - A Möricke
- Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - K Klein
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tuebingen, Germany
| | - M Schrappe
- Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Stanulla
- Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - R Houlston
- Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK
| | - R Weinshilboum
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
| | | | - A Metspalu
- Department of Biotechnology, Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia.,Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - L Milani
- Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - M Schwab
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tuebingen, Germany.,Department of Clinical Pharmacology, University Hospital Tuebingen, Tuebingen, Germany.,Department of Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany
| | - E Schaeffeler
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tuebingen, Germany
| |
Collapse
|
36
|
Dietl A, Farthmann J, Schwab M, Zollner U. Schwangerschafts- und geburtshilfliches Outcome bei fortgeschrittenem maternalen Alter. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
37
|
Matthaei J, Tzvetkov MV, Strube J, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R, Brockmöller J. Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2. Clin Pharmacol Ther 2016; 100:606-616. [DOI: 10.1002/cpt.444] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Revised: 07/27/2016] [Accepted: 07/29/2016] [Indexed: 12/24/2022]
Affiliation(s)
- J Matthaei
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - MV Tzvetkov
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - J Strube
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - D Sehrt
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - C Sachse-Seeboth
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - JB Hjelmborg
- Department of Epidemiology, Biostatistics and Biodemography; University of Southern Denmark; Odense Denmark
| | - S Möller
- Department of Epidemiology, Biostatistics and Biodemography; University of Southern Denmark; Odense Denmark
| | - U Halekoh
- Department of Epidemiology, Biostatistics and Biodemography; University of Southern Denmark; Odense Denmark
| | - U Hofmann
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen; Stuttgart Germany
| | - M Schwab
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen; Stuttgart Germany
- Department of Clinical Pharmacology; University Hospital Tübingen; Tübingen Germany
- Department of Pharmacy and Biochemistry; University of Tübingen; Tübingen Germany
| | - R Kerb
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen; Stuttgart Germany
| | - J Brockmöller
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| |
Collapse
|
38
|
Peters S, Schwab M, Faller H, Meng K. Wie sind die Voraussetzungen und Erwartungen von Hausärzten und Therapeuten hinsichtlich eines Schulungsangebots zur Bewegungsförderung. Gesundheitswesen 2016. [DOI: 10.1055/s-0036-1586551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Fisel P, Schaeffeler E, Schwab M. DNA Methylation of ADME Genes. Clin Pharmacol Ther 2016; 99:512-27. [PMID: 27061006 DOI: 10.1002/cpt.343] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 01/18/2016] [Accepted: 01/20/2016] [Indexed: 12/13/2022]
Abstract
The epigenetic regulation of expression of genes involved in the absorption, distribution, metabolism, and excretion (ADME) of drugs contributes to interindividual variability in drug response. Epigenetic mechanisms include DNA methylation, histone modifications, and miRNAs. This review systematically outlines the influence of DNA methylation on ADME gene expression and highlights the consequences for interindividual variability in drug response or drug-induced toxicity and the implications for personalized medicine.
Collapse
Affiliation(s)
- P Fisel
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.,University of Tübingen, Tübingen, Germany
| | - E Schaeffeler
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.,University of Tübingen, Tübingen, Germany
| | - M Schwab
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.,Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.,Department of Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany
| |
Collapse
|
40
|
Dahms C, Guenther A, Schwab M, Schultze T, Nowack S, Hoyer D, Ehrhardt J, Witte OW, Mayer G, Rupprecht S. Dysautonomia in prodromal α-synucleinopathy: peripheral versus central autonomic degeneration. Eur J Neurol 2016; 23:878-90. [PMID: 26842960 DOI: 10.1111/ene.12957] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 12/04/2015] [Indexed: 12/24/2022]
Abstract
BACKGROUND AND PURPOSE There is an urgent need for early predictive markers for the course of disease in prodromal α-synucleinopathies such as idiopathic rapid eye movement (REM) sleep behaviour disorder. Autonomic cardiac/vascular dysfunction is a prominent feature in advanced α-synucleinopathies, but its diagnostic value as an early neurodegenerative marker remains unclear. The latter may be complicated since synuclein-mediated neurodegeneration may involve central and peripheral components of the autonomic nervous system. METHODS The diagnostic value of autonomic symptoms and central and peripheral autonomic markers of blood pressure and heart rate regulation were prospectively evaluated in 20 subjects with idiopathic REM sleep behaviour disorder and 20 age-matched healthy controls. RESULTS Although subjects with REM sleep behaviour disorder showed no clinical autonomic symptoms, blood pressure (P ≤ 0.035) and heart rate response (P ≤ 0.065) were slightly diminished during orthostatic challenge. Autonomic dysregulation was distinctively reflected in lower resting heart rate (all components, P ≤ 0.05) and blood pressure variability (low frequency component, P ≤ 0.024) indicating peripheral cardiac/vascular denervation. In contrast, baroreflex sensitivity and central cardiac autonomic outflow (sympathovagal balance) were well preserved indicating intact central autonomic regulation. Heart rate variability [very low frequency component, receiver operating characteristic (ROC) area under the curve (AUC) 0.80, P ≤ 0.001] and blood pressure variability (low frequency component ROC AUC 0.73, P ≤ 0.01) but not baroreflex sensitivity and sympathovagal balance showed an excellent diagnostic accuracy in identifying subjects with REM sleep behaviour disorder and healthy controls. CONCLUSIONS Cardiac/vascular dysfunction in prodromal α-synucleinopathy arises from peripheral rather than from central autonomic degeneration. Autonomic indices encoded in heart rate and blood pressure variability are precise functional markers of early synuclein-mediated neurodegeneration.
Collapse
Affiliation(s)
- C Dahms
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - A Guenther
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - M Schwab
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - T Schultze
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - S Nowack
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - D Hoyer
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - J Ehrhardt
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - O W Witte
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - G Mayer
- Hephata Hospital, Schwalmstadt-Treysa, Germany
| | - S Rupprecht
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| |
Collapse
|
41
|
Schroth W, Winter S, Büttner F, Goletz S, Faißt S, Brinkmann F, Saladores P, Heidemann E, Ott G, Gerteis A, Alscher MD, Dippon J, Schwab M, Brauch H, Fritz P. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype. Breast Cancer Res Treat 2015; 155:85-97. [DOI: 10.1007/s10549-015-3651-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 11/26/2015] [Indexed: 01/08/2023]
|
42
|
Matthaei J, Brockmöller J, Tzvetkov MV, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R. Heritability of metoprolol and torsemide pharmacokinetics. Clin Pharmacol Ther 2015; 98:611-21. [DOI: 10.1002/cpt.258] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 09/02/2015] [Indexed: 12/22/2022]
Affiliation(s)
- J Matthaei
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - J Brockmöller
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - MV Tzvetkov
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - D Sehrt
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - C Sachse-Seeboth
- Institute for Clinical Pharmacology, University Medical Center, Göttingen; Georg-August University; Göttingen Germany
| | - JB Hjelmborg
- Department of Epidemiology, Biostatistics and Biodemography; University of Southern Denmark; Odense Denmark
| | - S Möller
- Department of Epidemiology, Biostatistics and Biodemography; University of Southern Denmark; Odense Denmark
| | - U Halekoh
- Department of Epidemiology, Biostatistics and Biodemography; University of Southern Denmark; Odense Denmark
| | - U Hofmann
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Department of Clinical Pharmacology; University of Tübingen; Stuttgart Germany
| | - M Schwab
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Department of Clinical Pharmacology; University of Tübingen; Stuttgart Germany
- Department of Clinical Pharmacology; University Hospital Tübingen; Tübingen Germany
| | - R Kerb
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Department of Clinical Pharmacology; University of Tübingen; Stuttgart Germany
| |
Collapse
|
43
|
Kramer K, Wolf S, Mayer B, Schmidt SA, Agaimy A, Henne-Bruns D, Knippschild U, Schwab M, Schmieder M. Frequence, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors. Neoplasia 2015; 17:134-40. [PMID: 25622906 PMCID: PMC4309732 DOI: 10.1016/j.neo.2014.12.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2014] [Accepted: 12/04/2014] [Indexed: 02/08/2023] Open
Abstract
Currently available data on prognostic implication of additional neoplasms in GIST miss comprehensive information on patient outcome with regard to overall or disease specific and disease free survival. Registry data of GIST patients with and without additional neoplasm were compared in retrospective case series. We investigated a total of 836 patients from the multi-center Ulmer GIST registry. Additionally, a second cohort encompassing 143 consecutively recruited patients of a single oncology center were analyzed. The frequency of additional malignant neoplasms in GIST patients was 31.9% and 42.0% in both cohorts with a mean follow-up time of 54 and 65 months (median 48 and 60 months), respectively. The spectrum of additional neoplasms in both cohorts encompasses gastrointestinal tumors (43.5%), uro-genital and breast cancers (34.1%), hematological malignancies (7.3%), skin cancer (7.3%) and others. Additional neoplasms have had a significant impact on patient outcome. The five year overall survival in GIST with additional malignant neoplasms (n = 267) was 62.8% compared to 83.4% in patients without other tumors (n = 569) (P < .001, HR=0.397, 95% CI: 0.298-0.530). Five-year disease specific survival was not different between both groups (90.8% versus 90.9%). 34.2% of all deaths (n = 66 of n = 193) were GIST-related. The presented data suggest a close association between the duration of follow-up and the rate of additional malignancies in GIST patients. Moreover the data indicate a strong impact of additional malignant neoplasms in GIST on patient outcome. A comprehensive follow-up strategy of GIST patients appears to be warranted.
Collapse
Affiliation(s)
- K Kramer
- Department of General and Visceral Surgery, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm Germany.
| | - S Wolf
- Department of Surgery, District-Hospital St. Gallen, Rorschacher Strasse 95, 9007 St.Gallen, Switzerland.
| | - B Mayer
- Institute of Epidemiology and Medical Biometry, Schwabstr. 13, University of Ulm, 89075 Ulm, Germany.
| | - S A Schmidt
- Department of Diagnostic and Interventional Radiology, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
| | - A Agaimy
- Institute of Pathology, University of Erlangen, Krankenhausstr. 8-10, 91054 Erlangen Germany.
| | - D Henne-Bruns
- Department of General and Visceral Surgery, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm Germany.
| | - U Knippschild
- Department of General and Visceral Surgery, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm Germany.
| | - M Schwab
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstraße 112, 70376 Stuttgart, Germany; Department of Clinical Pharmacology, University Hospital, Wilhelmstraße 56, 72074 Tübingen, Germany.
| | - M Schmieder
- Department of Internal Medicine, Alb-Fils-Kliniken, Eichertstr. 3, 73035 Goeppingen, Germany.
| |
Collapse
|
44
|
Wöckel A, Schwab M. Einladung. 1. Franken Fortbildung Frauengesundheit in Würzburg. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1557930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
45
|
Dietl A, Cupisti S, Beckmann MW, Schwab M, Zollner U. Pregnancy and Obstetrical Outcomes in Women Over 40 Years of Age. Geburtshilfe Frauenheilkd 2015; 75:827-832. [PMID: 26366002 DOI: 10.1055/s-0035-1546109] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2014] [Revised: 04/28/2015] [Accepted: 04/29/2015] [Indexed: 12/20/2022] Open
Abstract
Introduction: Delayed childbearing is increasing, and advanced maternal age has been associated with an increased risk of obstetrical complications. The purpose of this study was to evaluate pregnancy outcomes in women with advanced maternal age (≥ 40 years). Methods: Maternal and obstetrical data were collected from the Department of Obstetrics and Gynecology of the University of Wuerzburg for the period from 2006 to 2011. In this retrospective analysis we compared the outcomes for women aged ≥ 40 years (n = 405) with those of three younger subgroups (I: < 30 y; II: 30-34 y; III: 35-39 y). Results: Pregnant women older than 40 years had more chronic diseases such as hypertension, needed medical treatment more frequently and had a higher thrombosis risk. Pregnancy-induced diseases such as gestational diabetes, preeclampsia and pregnancy-associated hypertension occurred more often in women ≥ 40 years of age. Compared to mothers who were younger than 30 years, primiparous women ≥ 40 years had a more than four times higher overall cesarean section rate and four times higher elective cesarean section rate. Furthermore, they required longer hospital stays, both after cesarean section and after vaginal delivery. The preterm birth rate (≤ 32 weeks of gestation) was similar across the different age groups. Conclusions: The outcomes of pregnancy and childbirth and for newborns born to women ≥ 40 years did not vary significantly from those of younger women if the following conditions were met: a) pre-existing chronic diseases were treated medically and dietetically; b) pregnancy-induced morbidity was monitored regularly and controlled medically; c) women attended regular prenatal check-ups; d) a healthy lifestyle was adhered to during pregnancy, and e) delivery occurred in a perinatal center.
Collapse
Affiliation(s)
- A Dietl
- Department of Obstetrics and Gynecology, University of Freiburg i. Br., Freiburg i. Br
| | - S Cupisti
- Department of Obstetrics and Gynecology, University of Erlangen, Erlangen
| | - M W Beckmann
- Department of Obstetrics and Gynecology, University of Erlangen, Erlangen
| | - M Schwab
- Department of Obstetrics and Gynecology, University of Würzburg, Würzburg
| | - U Zollner
- Department of Obstetrics and Gynecology, University of Würzburg, Würzburg
| |
Collapse
|
46
|
Tremmel R, Fehr S, Battke F, Klein K, Schaeffeler E, Schwab M, Biskup S, Zanger U.. Adme-wide analysis of Copy Number Variation using Targeted exome resequencing and their functional relevance in Human Liver. Clin Ther 2015. [DOI: 10.1016/j.clinthera.2015.05.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Klein K, Fehr S, Tremmel R, Schaeffeler E, Winter S, Schwab M, Biskup S, Zanger U. Targeted Exome Resequencing: Adme Pharmacogenetics In Human Liver. Clin Ther 2015. [DOI: 10.1016/j.clinthera.2015.05.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
48
|
Walker B, Schmid E, Russo A, Schmidt EM, Burk O, Münzer P, Velic A, Macek B, Schaller M, Schwab M, Seabra MC, Gawaz M, Lang F, Borst O. Impact of the serum- and glucocorticoid-inducible kinase 1 on platelet dense granule biogenesis and secretion. J Thromb Haemost 2015; 13:1325-34. [PMID: 25944668 DOI: 10.1111/jth.12998] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2014] [Indexed: 02/04/2023]
Abstract
BACKGROUND Platelet secretion is critical to development of acute thrombotic occlusion. Platelet dense granules contain a variety of important hemostatically active substances. Nevertheless, biogenesis of platelet granules is poorly understood. OBJECTIVES Serum- and glucocorticoid-inducible kinase 1 (SGK1) has been shown to be highly expressed in platelets and megakaryocytes, but its role in the regulation of platelet granule biogenesis and its impact on thrombosis has not been investigated so far. METHODS AND RESULTS Electron microscopy analysis of the platelet ultrastructure revealed a significant reduction in the number and packing of dense granules in platelets lacking SGK1 (sgk1(-/-) ). In sgk1(-/-) platelets serotonin content was significantly reduced and activation-dependent secretion of ATP, serotonin and CD63 significantly impaired. In vivo adhesion after carotis ligation was significantly decreased in platelets lacking SGK1 and occlusive thrombus formation after FeCl3 -induced vascular injury was significantly diminished in sgk1(-/-) mice. Transcript levels and protein abundance of dense granule biogenesis regulating GTPase Rab27b were significantly reduced in sgk1(-/-) platelets without affecting Rab27b mRNA stability. In MEG-01 cells transfection with constitutively active (S422) (D) SGK1 but not with inactive (K127) (N) SGK1 significantly enhanced Rab27b mRNA levels. Sgk1(-/-) megakaryocytes show significantly reduced expression of Rab27b and serotonin/CD63 levels compared with sgk1(+/+) megakaryocytes. Proteome analysis identified nine further vesicular transport proteins regulated by SGK1, which may have an impact on impaired platelet granule biogenesis in sgk1(-/-) platelets independent of Rab27b. CONCLUSIONS The present observations identify SGK1 as a novel powerful regulator of platelet dense granule biogenesis, platelet secretion and thrombus formation. SGK1 is at least partially effective because it regulates transcription of Rab27b in megakaryocytes.
Collapse
Affiliation(s)
- B Walker
- Department of Cardiology and Cardiovascular Medicine, University of Tübingen, Tübingen, Germany
- Department of Physiology, University of Tübingen, Tübingen, Germany
| | - E Schmid
- Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital Tübingen, Tübingen, Germany
| | - A Russo
- Department of Physiology, University of Tübingen, Tübingen, Germany
| | - E-M Schmidt
- Department of Physiology, University of Tübingen, Tübingen, Germany
| | - O Burk
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
| | - P Münzer
- Department of Cardiology and Cardiovascular Medicine, University of Tübingen, Tübingen, Germany
- Department of Physiology, University of Tübingen, Tübingen, Germany
| | - A Velic
- Proteom Center Tübingen, University of Tübingen, Tübingen, Germany
| | - B Macek
- Proteom Center Tübingen, University of Tübingen, Tübingen, Germany
| | - M Schaller
- Department of Dermatology, University Hospital Tübingen, Tübingen, Germany
| | - M Schwab
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
- Department of Clinical Pharmacology, University Hospital, Tübingen, Germany
| | - M C Seabra
- Molecular Medicine, National Heart and Lung Institute, Imperial College London, London, UK
| | - M Gawaz
- Department of Cardiology and Cardiovascular Medicine, University of Tübingen, Tübingen, Germany
| | - F Lang
- Department of Physiology, University of Tübingen, Tübingen, Germany
| | - O Borst
- Department of Cardiology and Cardiovascular Medicine, University of Tübingen, Tübingen, Germany
- Department of Physiology, University of Tübingen, Tübingen, Germany
| |
Collapse
|
49
|
Rath D, Chatterjee M, Borst O, Müller K, Langer H, Mack AF, Schwab M, Winter S, Gawaz M, Geisler T. Platelet surface expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 is associated with clinical outcomes in patients with coronary artery disease. J Thromb Haemost 2015; 13:719-28. [PMID: 25660395 DOI: 10.1111/jth.12870] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Indexed: 12/18/2022]
Abstract
BACKGROUND Surface expression of stromal cell-derived factor-1 (SDF-1, CXCL12) on platelets is enhanced during ischemic events and plays an important role in peripheral homing of stem cells and myocardial repair mechanisms. SDF-1 effects are mediated through CXCR4 and CXCR7. Both CXCR4 and CXCR7 are surface expressed on human platelets and to a higher degree in patients with coronary artery disease (CAD) compared with healthy controls. In this study, we investigated the prognostic role of platelet CXCR4- and CXCR7 surface expression in patients with symptomatic CAD. METHODS AND RESULTS In a cohort study, platelet surface expression of CXCR4 and CXCR7 was measured by using flow cytometry in 284 patients with symptomatic CAD at the time of percutaneous coronary intervention (PCI). The primary combined end point was defined as all-cause death and/or myocardial infarction (MI) during 12-month follow-up. Secondary end points were defined as the single events of all-cause death and MI. We found significant differences of CXCR4 values in patients who developed a combined end point compared with event-free patients (mean MFIAUTHOR: Please define MFI at first use. 3.17 vs. 3.44, 95% confidence interval [CI] 0.09-0.45) and in patients who subsequently died (mean MFI 3.10 vs. 3.42, 95% CI 0.09-0.56). In multivariate Cox regression analysis, lower platelet CXCR4 levels were independently and significantly associated with all-cause mortality (hazard ratio 0.24, 95% CI 0.07-0.87) and the primary combined end point of all-cause death and/or MI (hazard ratio 0.30, 95% CI 0.13-0.72). CONCLUSION These findings highlight a potential prognostic value of platelet expression CXCR4 on clinical outcomes in patients with CAD.
Collapse
Affiliation(s)
- D Rath
- Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, University Tübingen, Tübingen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Arlanov R, Lang T, Jedlitschky G, Schaeffeler E, Ishikawa T, Schwab M, Nies AT. Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant. Pharmacogenomics J 2015; 16:193-201. [PMID: 25896536 DOI: 10.1038/tpj.2015.27] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Revised: 02/23/2015] [Accepted: 03/02/2015] [Indexed: 11/09/2022]
Abstract
Multidrug resistance protein 8 (ABCC11) is an efflux transporter for anionic lipophilic compounds, conferring resistance to antiviral and anticancer agents like 5-fluorouracil (5-FU). ABCC11 missense variants may contribute to variability in drug response but functional consequences, except for the 'earwax variant' c.538G>A, are unknown. Using the 'Screen and Insert' technology, we generated human embryonic kidney 293 cells stably expressing ABCC11 missense variants frequently occurring in different ethnic populations: c.57G>A, c.538G>A, c.950C>A, c.1637C>T, c.1942G>A, c.4032A>G. A series of in silico prediction analyses and in vitro plasma membrane vesicle uptake, immunoblotting and immunolocalization experiments were undertaken to investigate functional consequences. We identified c.1637C>T (T546M), previously associated with 5-FU-related toxicity, as a novel functionally damaging ABCC11 variant exhibiting markedly reduced transport function of 5-FdUMP, the active cytotoxic metabolite of 5-FU. Detailed analysis of 14 subpopulations revealed highest allele frequencies of c.1637C>T in Europeans and Americans (up to 11%) compared with Africans and Asians (up to 3%).
Collapse
Affiliation(s)
- R Arlanov
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Stuttgart, Germany
| | - T Lang
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Stuttgart, Germany
| | - G Jedlitschky
- Department of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald, Greifswald, Germany
| | - E Schaeffeler
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Stuttgart, Germany
| | - T Ishikawa
- RIKEN Center for Life Science Technologies, Yokohama, Japan
| | - M Schwab
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Stuttgart, Germany.,Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital of Tübingen, Tübingen, Germany
| | - A T Nies
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Stuttgart, Germany
| |
Collapse
|